A nanobody-based vaccine strategy to combat CoVID-19

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2020
    2021
  • Known Financial Commitments (USD)

    $442,500
  • Funder

    National Institutes of Health (NIH)
  • Principle Investigator

    Pending
  • Research Location

    United States of America, Americas
  • Lead Research Institution

    BOSTON CHILDREN'S HOSPITAL
  • Research Category

    Vaccines research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags

    Gender

  • Study Subject

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

SummaryThe development of a vaccine that protects against SARS-CoV-2, the coronavirus responsible for the currentpandemic (COVID-19), is urgently needed. We have developed camelid-derived antibody fragments -nanobodies - that target surface proteins on mouse and human antigen presenting cells. These targets includeclass II MHC products and the integrin alpha M (CD11b). By attaching to these nanobodies various antigens inthe form of proteins or peptides, we can elicit stronger B and T cell responses against the attached payloadswhen compared to the corresponding 'free' antigens. In particular, adducts composed of the anti-CD11bnanobody with peptides of viral origin induced a protective cytotoxic CD8 T cell response in a humanpapillomavirus model and inspire confidence that a similar outcome may be accomplished for SARS-CoV-2. Wepropose to apply these strategies to generate strong adaptive immune responses against SARS-CoV-2 antigens.The anti-mouse and anti-human class II MHC-specific nanobodies recognize all allotypes and will be used totarget antigens to mouse and human class II MHC products in normal and HLA-DR4 transgenic mice. CD4 Tcell and antibody responses will be analyzed in these studies. Adducts composed of the CD11b nanobody andCOVID-19 antigenic peptides will be used to elicit CD8 T cell responses in normal and HLA-A2 transgenic mice.For the most immunogenic SARS-CoV-2 antigens, we shall identify the minimal peptides recognized for possibleinclusion in future vaccine preparations.